|A Hookworm Infection Study in Healthy Adults||This study is being conducted to determine the optimal dose of infectious hookworm larvae that is safe to give to healthy adults, and that leads to an infection with adult worms in the intestine. Hookworm is a parasitic worm that can live for several years in the intestine of humans, feeding on the blood of the people they infect. Study participants will provide routine stool and blood samples and will receive anti-worm medication 3 months from application of the larvae to treat the infection. This study is looking to enroll males or females, 18-45 years of age in good general health, who are available for the duration of the study (6 months). Subjects must be HIV, Hep-B and Hep-C negative.
|A Phase III, randomised, double-blind, multicentre, parallel group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults||The study is being conducted to learn if the combination of two medications, one called dolutegravir (DTG) and one called lamivudine (3TC), is an effective treatment for adults who have not been treated for HIV before.